Moderna shares tumble as leaked Phase 3 melanoma vaccine data triggers sell-the-news move

Moderna shares tumble as leaked Phase 3 melanoma vaccine data triggers sell-the-news move

N
News Editor
2026-10-23 03:40:24
Moderna shares fell sharply in Thursday trading after Phase 3 data tied to its personalized melanoma vaccine, developed with Merck, leaked ahead of schedule. The market reaction came even though the reported clinical readout was positive. According to MSX.COM data, Moderna dropped to an intraday low of $180.80, down about 26.45% from the previous close and roughly 28.95% below its Oct. 21 high of $254.48. The stock later recovered part of the loss and finished at $202.63, down 17.57% on the day. Reuters reported that the Moderna-Merck combination therapy reduced the risk of melanoma recurrence or death by 42%, while cutting the risk of distant metastasis or death by 38%. After the stock had risen more than 500% at one point this year, the market had already priced in high expectations for both efficacy and future commercialization. UBS and other institutions said the decline looked closer to a classic sell-the-news trade, with investors reassessing whether the current clinical progress can justify the valuation gains seen earlier.

Moderna shares sold off sharply on Thursday after Phase 3 data related to its personalized melanoma vaccine, co-developed with Merck, leaked ahead of schedule, even as the reported clinical results were positive.

According to MSX.COM data, Moderna fell to an intraday low of $180.80 during U.S. trading, down about 26.45% from the previous close and roughly 28.95% below its Oct. 21 swing high of $254.48. The stock later rebounded and finished at $202.63, closing down 17.57%.

Reuters reported that the combined therapy from Moderna and Merck reduced the risk of melanoma recurrence or death by 42%, and lowered the risk of distant metastasis or death by 38%.

After Moderna had risen more than 500% at one point this year, the market had already built in elevated expectations for the vaccine's efficacy and its commercialization prospects. UBS and other institutions said the drop looked more like a classic sell-the-news reaction, as investors reassessed whether the current clinical outcome can support the stock's earlier valuation gains.

This article was originally published by Bit.Fan. For more cryptocurrency news and market insights, visit www.bit.fan.
8300

Disclaimer:

The market information, project data, and third-party content displayed on this platform are for industry information sharing only and do not constitute any form of investment advice or return commitment.

Cryptocurrency trading carries high risks. Users should fully assess their risk tolerance and make independent decisions. All profits, losses, and legal responsibilities are borne by the users themselves.